AntoXa

Life-saving biodefense solutions

  • About Us
    • Management Team
  • Products
  • Investors
  • News
  • Contact
You are here: Home / Global Demand for Biodefense Therapeutics

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and pandemic diseases. In the U.S., spending on military and civilian biodefense initiatives has averaged US$5.4 billion over the past decade, and the global market is expected to reach US$17 billion by 2024.

Billions allocated for strategic stockpiles

Governments and military agencies represent the primary market for the AntoXa products. These agencies have large budgets for developing and stockpiling medical countermeasures. For examples, the Strategic National Stockpile in the United States has been allocated US$50 billion snice 2001 to create a national repository of life-saving pharmaceuticals, including chemical antidotes and antitoxins. AntoXa, through PlantForm, has established positive relationships with the Canadian, American and Australian departments of defence and has to date secured greater than $3.8 million towards its medical countermeasure programs.

Latest News

AntoXa and SwiftPharma to present plant-made anti-ricin antibody technology to NATO expert panel

August 14, 2024

GUELPH, Ont., Canada, August 14, 2024 — AntoXa Corporation, a Canadian ...
Read more >

New Patent for AntoXa’s Plant-Made Anti-Ricin Antibody Manufacturing Process

January 30, 2024

GUELPH, Ont., Canada, January 30, 2024 — The Canadian Intellectual ...
Read more >

AntoXa Corporation and SwiftPharma Sign Exclusive Collaboration Agreement to Support the Development and Commercialization of a Plant-Made Antibody Against Ricin Exposure

September 5, 2023

GHENT, Belgium and TORONTO, Canada, September 5, 2023 – AntoXa ...
Read more >

About Us

Plant-made biopharmaceuticals for a safer world. AntoXa Corporation is a Canadian biopharmaceutical company developing medical countermeasures to protect military and civilian personnel from biological and chemical agents that might be used in terrorist attacks, as well as outbreaks of naturally ...
Read more >

Global Demand for Biodefense Therapeutics

Governments are investing billions of dollars preparing for potential bioterrorism attacks and ...
Read more >

Subscribe to our Newsletter

vivoXPRESS® MANUFACTURING SYSTEM
The plant-based vivoXPRESS® manufacturing platform offers several advantages over the mammalian and bacterial cell culture systems used to produce most recombinant protein pharmaceuticals. Here’s how it works.

BioPharming Info Centre

Biopharming, also known as plant molecular farming, refers to the use of genetically modified plants to produce a wide range of pharmaceuticals and industrial products. See our Biopharming Info Centre to Learn more about the science and history of using plants to produce complex therapeutic proteins.

Copyright © 2025 · AntoXa Corporation | Site by Curry Gunn & Associates